News for Health Professionals Archive - December 2013

December 2, 2013

• Report: Big Data Can Change Patient Recruitment
• Shire in Generic Adderall XR Deal
• Janssen: Xeplion Effective in Patients with Schizophrenia
• Healios, Dainippon Sumitomo Pharma in $50.6M Deal
• Forest Announces Plans to Streamline Operations
• Forest to Buy U.S. Marketing Rights to Merck's Saphris
• Lilly, Boehringer Ingelheim Launch Diabetes Survey
• Pharma Should Factor Medication Adherence Into Drug Development
• Elton John AIDS Foundation and Mylan Give $1 Million to Nigeria for the Elimination of Mother-to-Child Transmission of HIV

December 3, 2013

• Obesity Drug Highlights Novo Nordisk Presentation
• Pharma Firms Investing More in New Products but Returns Wane
• Celgene, OncoMed in $177M Cancer Stem Cell Deal
• Analysts: New Cholesterol Treatment Guidelines Present Challenges
• Medical Advertising Hall of Fame elects Thomas Domanico, Carroll Dowden, and Clive Lewis, and gives Service to Industry Award to Barbara Pritchard
• Grant to Study Impact of Quality and Price Transparency on Consumer Choice
• PrimeraDx Receives 510(k) Clearance from FDA
• Roche Launches Cobas P 480 Instrument
• Cochlear Announces the FDA Clearance of the Baha 4 Attract System
• Physicians Interactive Expands Access to CME Content
• Fake it until you become it: Lessons from the Healthcare Businesswomen’s Association leadership conference
• Advanced Clinical Selects Veeva Vault eTMF as Standard for New eTMF Services
• VeriMed Launches Radar

December 4, 2013

• Osiris CEO Resigns, Shares Slip
• Boehringer Ingelheim Venture Fund to Invest $130M in Boston Area
• Teva In-Focus: A Webinar Series for the Investment Community Focusing on Teva’s R&D Activities
• AstraZeneca Gets $76M in Prilosec Case
• Teva, Takeda in Copaxone Deal in Japan
• 'Dancing with the Stars' Star Partners With Teva
• CTI, GKV Reach Agreement on Pixuvri Pricing
• Harvard Bioscience Realigning, Cutting 13% of Jobs
• PACIFIC Communications Named Agency of Record for SkinMedica
• Ambit Biosciences Falls on Slower Path for Drug
• Pfizer Expands Clinical Trial Data Access Policy
• Rho Principal Programmer Named Conference Chair of Southeastern SAS User’s Group for 2016 Term
• Kenco Appoints Kevin Fletcher Senior Vice President of Transportation Services
• Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers
• Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
• Celator Pharmaceuticals Announces Appointment of Derek Miller as Chief Business Officer
• Oxford Immunotec Global PLC Announces Appointment of Herm Rosenman to the Board of Directors
• Adaptimmune appoints Dr Jonathan Knowles as Chairman of the Board
• OXiGENE Appoints Frederick W. Driscoll to Its Board of Directors
• CereSpir Incorporated Appoints Richard Margolin, MD, as Vice President, Clinical Development

December 5, 2013

• Research Indicates that Physicians Prefer Digital Media
• Doctors Prefer Digital Media to In-Person Sales Reps
• Arca Can Start Human Testing of Heart Drug Gencaro
• Chemocentryx Shares Edge Higher
• Crossix POC Impact Increases Campaign Measurement Accuracy
• Novo Nordisk Study: Only 29% of Diabetics Say Doc Asks for Their Input
• Report: Approval of First Biosimilar Monoclonal Antibody In Europe Has Major Implications
• Frost & Sullivan: Minimally Invasive Approach Boosts Demand for Endoscopy Devices in Australia, South Korea and Southeast Asia
• Ventana Receives FDA Clearance
• Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
• Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations
• Inventiv Health Hires Senior Life Sciences Executive to Oversee Expansion of Multi-Faceted Operations in India
• Vision-Sciences Promotes Howard Zauberma
• Cho Named President of Harlan Korea
• Benchworks Promotes Thompson, Jamison
• Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors
• Melinta Therapeutics Appoints Sue Cammarata, M.D. as Chief Medical Officer
• INC Research Appoints Gregory M. Hockel, PhD to Lead Regulatory Consulting Practice
• Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer
• Ad-ventures in marketing VII
• Report: VC Funding in Life Sciences Falls Behind
• Mobile maze

December 6, 2013

• Celgene Rises As UBS Upgrades Shares to 'Buy'
• Novartis: Multiple Myeloma Drug Meets Phase III Endpoint
• GSK Launches Global Consortium
• EMA Starts In-Depth Review of Iclusig
• Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement
• Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test
• Nearly Half of U.S. Adults Opted for Flu Vaccine in 2012
• Nearly Half of U.S. Adults Opted for Flu Vaccine
• New Information on Defined Contribution Health Benefits Published
• Saint Luke's Heart Attack Survival Rates are Better than 98 Percent of Hospitals in the Nation
• Crossix POC Impact Delivers Campaign Measurement Accuracy
• Glaxo and its transparency commitment
• The Last Word - How “The best thing that could ever happen to you” – happened to me
• To the Point - Technical difficulties
• Assessing future loss of exclusivity scenarios
• Facts and Figures - November 2013
• Most-recognized brands, Oncology and Hematology, November 2013

December 9, 2013

• Ceiba Solutions Launches iSwarm Windows Phone 8 App
• US Approves Breakthrough Hepatitis C Drug
• App Allows Users to Sift through Social Media Content
• Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak
• OIG Subpoenas United Therapeutics Over Marketing
• Publicis Groupe Broadens Healthcare Expertise
• Acura: FDA to Review Painkiller Study
• Sanofi US Launches Second Innovation Challenge
• Janssen Starts Drug Donation Program for HIV Treatment-Experienced Children
• Publicis Looks to Verilogue to Heighten Exceptionality via Acquisition
• Practical advice for pharma SEO
• PCPs facing e-prescribing challenges
• More than half now write e-prescriptions
• Internet resources support consumer decision making
• The importance of creative endurance in developing winning ads

December 10, 2013

• Teva Provides Two Scenarios for Outlook
• Novo Nordisk Reported to the Police By the Danish Financial Supervisory Authority for Violating Disclosure Obligation
• Novo Nordisk Reported to Police for Breaching Disclosure Rules
• Eisai Announces New Partnership with Esteve
• Report: Wearable Medical Devices Market is Expected to Reach $5.8B Globally in 2019
• Bristol-Myers Squibb Foundation Announces Two Grants to Fund Cancer Nursing Centers
• American Medical Systems Receives FDA 510(k) Clearance
• Anavex Appoints Clinical Design Expert to Scientific Advisory Board
• Hiroharu Okochi Named New President of Harlan Japan
• Nuevolution Appoints Ton Berkien as Chief Business Officer

December 11, 2013

• Activist Hedge Fund Seeks Higher Bid in Pharmaceutical Merger
• Actavis Announces Tentative Agreement Related to Asacol Patent Challenge
• Savient to Sell Substantially All Assets to Crealta Pharmaceuticals
• Study: Long-term Use of Common Heartburn and Ulcer Medications Linked to Vitamin B12 Deficiency
• CVS Caremark, Cardinal Health to Form Joint Generic Venture
• GSK Invests $328M in Manufacturing, Science
• Mobius Imaging Receives ISO 13485 Certification
• Report: Antimicrobial Coatings Market Worth $2.9 Billion by 2018
• Medimmune, the Johns Hopkins University Announce 5-Year, $6.5M Collaboration
• Johnson & Johnson Innovation Establishes Network of Partnering Offices in UK Life Sciences Clusters
• Prescription Drug Abusers, Sellers Now on VeriMed's Radar
• Report Names Top 10 Health Industry Issues for 2014
• CMI/Compas: PCPs, Pharma Should Let Sunshine Act In
• Report Identifies Top 10 Industry Concerns for 2014
• FDA Approves First Generic Versions of Antidepressant Drug Cymbalta

December 12, 2013

• Vivus, Sanofi in Avanafil Pact
• Study: GSK's FluLaval Vaccine Effective in Kids
• FDA Approves First Generic Versions of Cymbalta
• Emergent BioSolutions to Buy Cangene for $222M
• Ethicon Receives 510(K) Clearance for Harmonic Focus+ Shears
• Abstral Launched in Japan
• Susan Duffy Joins McCann RCW As President
• For Engagement, DIG Looks toward Future

December 13, 2013

• OIG Subpoenas Insys Therapeutics
• Merck KGaA: Allergopharma Plans to Invest $55M in Production Facility
• Doximity Takes on Physician Shortage with Launch of Talent Finder
• FDA Advisory Panel Votes Favorably on the Boston Scientific WATCHMAN Left Atrial Appendage Closure Device
• St. Jude Medical Gains CE Mark for 25 mm Portico Transcatheter Aortic Heart Valve
• New FDA approved pre-surgical treatment for cleft lip/palate
• Psychiatrists Less Likely to Accept Insurance Than Other Physicians
• Congress Moves Closer To Changing How Medicare Pays Doctors
• New Survey Reveals Employers' Plans, Preferences and Challenges Related to Private and Public Health Insurance Exchanges
• AMN Healthcare Survey: Hospital Executives See Continued Shortage of Physicians, Nurses and Advanced Practitioners
• PwC's Health Research Institute Identifies the Top 10 Health Industry Issues for 2014
• FDA Allows Marketing of First Device to Relieve Migraine Headache Pain

December 16, 2013

• GlaxoSmithKline Raising Stake in India
• Endo to Acquire Specialty Pharmaceutical Company NuPathe
• Hemispherx Biopharma Accelerates Program to Evaluate Ampligen/FluMist
• AcelRx and Grunenthal Announce Collaboration for EU Commercialization of Zalviso
• Apricus Expands Exclusive License Agreement to Market Vitaros
• EMD Serono's Redesigned Fertility Pen Available for Distribution in U.S.
• Doximity's Talent Finder Grants Employment Opportunities

December 17, 2013

• Lonza Amends Contract with Orange Business Services
• Trinity Pharma Raises $15M for Life Sciences Cloud Analytics
• GlaxoSmithKline to Change the Way it Markets Drugs
• Biogen Idec, Samsun BIoepis in Biosimilar Deal
• Boston Scientific Announces CE Mark Approval
• Report: Continuous Glucose Monitoring Market will Reach $568.5 Million Globally by 2020
• Almiral to Buy Aqua Pharmaceuticals for Up to $380M
• Evotec, Yale University to Collaborate on Cancer Therapy
• Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio Assay
• Digitas Health Appoints SVP of Social Strategy
• Pfizer Settles Viagra Patent Litigation With Teva
• Lock Up Your Medicines to Protect Children and Teens This Holiday Season

December 18, 2013

• Hanmi Launches Generic Nexium
• French Regulators Back Zostavax Vaccination
• GSK, ViiV: Lupin Generic Does Not Infringe Trizivir Patent
• Mylan Settles Targretin Suit
• Ocera Therapeutics, Roche in Discovery Deal
• Study: MCC Firms Get $100M From Pharma
• Branded or Generic? Adults Share Preferences in Study

December 19, 2013

• AstraZeneca to Buy BMS' Diabetes Stake for $4.1B
• ECRI Institute Helps Hospitals Address Joint Commission's 2014 Alarm Safety Goal
• Forest: New Fetzima Launched in U.S.
• Judicial Watch: Massive Health Insurance Policy Cancellations Resulting From Obamacare Mandates
• Sandoz Begins Phase III Clinical Trial for Biosimilar Adalimumab
• Algeta Board Backs Bayer $2.9B Buy Offer
• Pfizer Settles Viagra Patent Litigation With Teva
• Counterfeiters and Illicit Drug Smugglers Using Canada to Sell Fake Meds
• Report: Health R&D Spending Moves Slowly Upward
• HealthSTAR Communications Launches New Subsidiary

December 20, 2013

• Jazz Pharmaceuticals to Buy Gentium for $1B
• FDA Sends Amarin Letter over Webcast Invitation
• FDA Sends Letter to Covis Over Physician Letter
• Merck Launches Weight Managment Intervention Business
• Philips receives FDA clearance for First-Ever Spectral Breast Density Measurement Application
• Baxter Completes CE Mark Approval for VIVIA Hemodialysis System in Europe
• Sobi to Take Direct Responsibility for Orfadin in the US, Canada and Latin America
• Study: Most Workers Satisfied With Pay-Benefits Balance
• The Last Word - Be credible – or be cooked
• ACOs rising: Strategic opportunities in the evolution of accountable care organizations
• Facts & Figures - December 2013
• Consumer shift offers opportunity to pharma
• Most-recognized brands: Anti-infectives, December 2013

December 23, 2013

• EU OKs Erbitix Labeling
• FDA Allows Marketing of New Stent for Treating Pseudocysts of the Pancreas
• Ariad Resumes Selling Iclusig
• Rubicon Genomics Reports Surge In 2013 Sales Of Its Nucleic Acid Library Prep Kits
• Brazil's National Health System Currently Provides Coverage for 22 Drugs that are Distributed Free of Charge to Over 300,000 HIV-Infected Patients
• Shifting sands
• Healthcare Agency Roundtable 2013
• Online marketplace for physicians
• Cegedim launches social site for docs
• Facts and figures, Interactive Digital Marketing, December 2013
• Mobile usage transforming doc/patient relations
• Ad agency people on the move, December 2013
• Palio+Ignite names new leaders
• Publicis acquires Heartbeat Ideas
• BMS makes changes to senior management team
• People on the move, December 2013
• New emerging markets leader for Lilly
• Resolutions for 2014
• Recall of Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

December 26, 2013

• Hi-Tech Settles Texas Pricing Probe for $25M
• Report: Drug Device Combination Products Market Expected to Reach $115.1B Globally in 2019
• Warner Chilcott Files ANDA for NuvaRing
• Dainippon Sumitomo Pharma Sets Up Oncology Clinical Development Unit
• Sagent Pharmaceuticals Launches Octreotide Acetate Injection
• Reports Indicate Co-Managed Care Popular Among Older Adults with Low Back Pain
• Small Business Health Insurance Alternatives
• Hospital-Diagnosed Maternal Infections Linked to Increased Autism Risk

December 27, 2013

• ANI Pharmaceuticals Buys 31 Generic Drug Products from Teva
• Astellas, Immuno-Biological Laboratories in Silkworm Deal
• Shire Extends Tender Offer for ViroPharma
• Report: Focus on Compliance Reduces Risk for Payers in the Medicare and Medicaid Markets

December 30, 2013

• Thyroid Tops List of Endocrinologists' Most Searched

December 31, 2013

• Monthly News Roundup - December 2013